Alzheimer's Disease and the Amyloid β Protein: What Is the Role of Amyloid ?
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is characterized by the deposition of amyloid in the extracellular compartment of the brain in the form of congophilic amyloid angiopathy (CAA) and amyloid plaques (APs). Intracellular neurofibrillary tangles (NFTs) (88) formed from the abnormally phosphorylated cytoskeletal protein tau are also seen (52). The identification of the amyloid β protein (Aβ) in CAA and APs (28 ; 58) led to the cloning of the amyloid protein precursor (APP) (44). The discovery of familial AD (FAD) mutations in the APP gene (10 ; 29 ; 63 ; 64 ; 86) has supported the view that a defect in APP metabolism or function is directly involved in AD pathogenesis. The demonstration that mutations in the tau gene can lead to non-Alzheimer dementias with neurofibrillary pathology, lacking Aβ plaques (reviewed by 81), has reinforced the view that the NFTs are a secondary phenomenon in the pathogenesis of AD. It has long been argued that the deposition of amyloid is an early step in AD pathogenesis (58 ; Hardy and Higgins, 1992 ; 57). The term amyloid refers to insoluble proteinaceous deposits that are congophilic and exhibit red-green birefringence in the presence of plane polarized light (45). Implicit in much of the research on the role of APP and Aβ has been the assumption that deposits of amyloid are toxic to the brain (42) and that these deposits are the underlying cause of AD. The observation that Aβ peptides when "aged" (incubated to form amyloid fibrils) become toxic to neurons in culture (94 ; 22 ; 46 ; 66 ; 38) has further supported this view. The amyloid cascade hypothesis of AD, as formalized by Hardy and Higgins (35), states that Aβ"precipitates to form amyloid and, in turn, causes neurofibrillary tangles and cell death." However, this hypothesis has been challenged (see, e.g., 16 ; 34). It has been argued that the deposition of amyloid does not correlate with dementia (89 ; 2 ; 71 ; 72 ; 5), although the failure to observe a correlation may be related to the method by which AP load is measured (14). Whether amyloid deposits have a pathogenic role remains a controversial issue. Some of the neuropathological changes occurring in the AD brain were first described by Alzheimer (1). Extracellular deposits of amyloid in the form of APs and CAA, as well as intracellular NFTs, are major features of AD pathology (68). The major protein constituent of CAA and APs is a 4-kDa polypeptide termed the amyloid protein or Aβ (28 ; 58). A partial amino acid sequence of Aβ was used to clone a cDNA encoding a protein now referred to as the APP, which has features of an integral type I transmembrane glycoprotein (44). The APP gene contains 18 exons spanning >170 kb (95). The region encoding the Aβ sequence comprises part of exons 16 and 17 and contains between 40 and 43 amino acid residues that extend from the ectodomain into the transmembrane domain of the protein (Fig. 1). Primary structure of APP. Upper panel : APP is expressed initially as a type I transmembrane glycoprotein containing a large N-terminal ectodomain, a short transmembrane (TM) domain of hydrophobic amino acid residues, and a relatively short C-terminal cytoplasmic domain. The Aβ sequence makes up part of the ectodomain and extends partly into the TM domain. The APP gene encodes a protein containing a signal peptide sequence (SP), a cysteine-rich domain, a region rich in acidic residues, a domain with homology to Kunitz-type protease inhibitors (KPI), and a region sharing homology to the OX-2 protein. mRNA splicing can produce forms that lack the KPI or OX-2 domain. Lower panel : Amino acid sequence of the Aβ region of APP. Large arrows show the major sites of cleavage for α-, β, and γ-secretases. Small arrows show known FAD mutations. FIG. 1. It is now known that Aβ is a normal product of APP processing (32 ; 30 ; 21). The major route of APP processing is by α-secretase, an enzyme that cleaves within the Aβ sequence (20). Cleavage by β- and γ-secretases at the N- and C-terminal ends of the Aβ sequence liberates the Aβ polypeptide, which can subsequently be secreted from cells (21 ; 30 ; 31). The major form of Aβ that is secreted contains 40 amino acids (Aβ1-40). However, minor species containing 42 or 43 amino acid residues (Aβ1-42/43) are also produced. These extended forms of Aβ aggregate more readily and may seed amyloid fibril polymerization during the early stages of plaque formation (42). The strongest evidence for a pathogenic role for APP or Aβ comes from genetic studies of early-onset FAD (33). Several FAD mutations have been found in the APP gene. All of these mutations have been found to cluster close to the amyloid sequence in APP. Mutations at codon 716 (Florida), 717 (London), and 723 (Australian) cause an increased proportion of γ-secretase cleavage at position 42 or 43 in the amyloid sequence (Fig. 1 and Table 1). A mutation found at codons 670 and 671 in a Swedish kindred results in increased β-secretase cleavage (8 ; 43), whereas a point
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Cited by
Multiple neural systems controlling food intake and body weight
Berthoud, H.-R. (2002) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(02)00014-3 · Cited by 725
Regulation of APP cleavage by α‐, β‐ and γ‐secretases
Nunan, J., & Small, D. H. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02076-7 · Cited by 512
Self-citationAlzheimer's disease and Aβ toxicity: from top to bottom
Small, D. H., Mok, S. S., & Bornstein, J. C. (2001) · Nature Reviews Neuroscience · doi:10.1038/35086072 · Cited by 394
Self-citationAbramov, A. Y., Canevari, L., & Duchen, M. R. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-12-05088.2003 · Cited by 337
Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury
Franz, G., Beer, R., Kampfl, A., Engelhardt, K., Schmutzhard, E., Ulmer, H., & Deisenhammer, F. (2003) · Neurology · doi:10.1212/01.wnl.0000063313.57292.00 · Cited by 217
Metadata
- Authors
- Small, D. H., & McLean, C. A.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 1999-08
- Volume
- 73
- Issue
- 2
- Pages
- 443-449
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1526863987
- Cited by
- 143
- References
- 38
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alzheimer's Disease and the Amyloid β Protein: What Is the Role of Amyloid ? https://app.cochat.ai/papers/10.1046/j.1471-4159.1999.0730443.x
- The paper
- Small, D. H., & McLean, C. A. (1999). Alzheimer's Disease and the Amyloid β Protein: What Is the Role of Amyloid ? Journal of Neurochemistry. https://doi.org/10.1046/j.1471-4159.1999.0730443.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.